Research map: Angiosarcoma: adaptive designs leveraging vascular biology and antiangiogenic repurposing

Back to the article

Papers in this map

  1. Angiosarcoma · Robin Young · 2010 · 978 citations · Cited by this paper
  2. The potential impact of glucagon-like peptide 1 receptor agonists for the treatment of endometrial carcinoma · 2026 · Related
  3. Adaptive designs in clinical trials: why use them, and how to run and report them · Philip Pallmann · 2018 · 873 citations · Cited by this paper
  4. Emerging immune checkpoint inhibitor strategies in cervical cancer: a scoping review of ongoing clinical trials · 2026 · Related
  5. Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study · Nicolas Penel · 2008 · 696 citations · Cited by this paper
  6. Portal vein resection in pancreatic cancer: from technical feasibility to biological patient selection · 2026 · Related
  7. Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas · Robert G. Maki · 2009 · 576 citations · Cited by this paper
  8. The evolving survival landscape in advanced non-small cell lung cancer: an interrupted time series analysis · 2026 · Related
  9. Adaptive Designs for Clinical Trials · Deepak L. Bhatt · 2016 · 511 citations · Cited by this paper
  10. Quantitative and qualitative fecal immunochemical tests for colorectal cancer screening in Kazakhstan: a comparative study · 2026 · Related
  11. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas · Mark Agulnik · 2012 · 392 citations · Cited by this paper
  12. Frailty is not ECOG: why performance status alone is no longer enough in anticancer therapy · 2026 · Related
  13. Consistent MYC and FLT4 gene amplification in radiation‐induced angiosarcoma but not in other radiation‐associated atypical vascular lesions · Tianhua Guo · 2010 · 352 citations · Cited by this paper
  14. Can we consider stopping hepatocellular carcinoma surveillance in low-risk patients with hepatitis B? · 2026 · Related
  15. MYC High Level Gene Amplification Is a Distinctive Feature of Angiosarcomas after Irradiation or Chronic Lymphedema · Johanna Manner · 2009 · 322 citations · Cited by this paper
  16. Association of neoadjuvant chemotherapy with outcomes in patients with elevated preoperative Ca 19–9 undergoing pancreatic ductal adenocarcinoma resection · 2026 · Related
  17. Recurrent PTPRB and PLCG1 mutations in angiosarcoma · Sam Behjati · 2014 · 317 citations · Cited by this paper
  18. Cancer genome profiling in sarcomas: current status and future perspectives in Japan · 2026 · Related
  19. The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research · Corrie Painter · 2020 · 279 citations · Cited by this paper
  20. Emerging trends in early-onset gastrointestinal cancers - a comparative review with late-onset cancers · 2026 · Related
  21. KDR Activating Mutations in Human Angiosarcomas Are Sensitive to Specific Kinase Inhibitors · Cristina R. Antonescu · 2009 · 274 citations · Cited by this paper
  22. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab · Ciara Marie Kelly · 2020 · 213 citations · Cited by this paper
  23. Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial · Isabelle Laure Ray-Coquard · 2015 · 193 citations · Cited by this paper
  24. Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO) · Isabelle L. Ray-Coquard · 2012 · 192 citations · Cited by this paper
  25. Inhibiting the VEGF–VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor · Min S Park · 2010 · 172 citations · Cited by this paper
  26. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) · Michael J Wagner · 2021 · 168 citations · Cited by this paper
  27. MYC amplification and overexpression in primary cutaneous angiosarcoma: a fluorescence in-situ hybridization and immunohistochemical study · Wonwoo Shon · 2013 · 136 citations · Cited by this paper
  28. Bayesian statistics for clinical research · Ewan C. Goligher · 2024 · 131 citations · Cited by this paper
  29. The utility of ERG, CD31 and CD34 in the cytological diagnosis of angiosarcoma: an analysis of 25 cases · Harold Clifford Sullivan · 2014 · 127 citations · Cited by this paper
  30. Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study · Eddy Pasquier · 2016 · 123 citations · Cited by this paper
  31. Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications · Yunhe Liu · 2025 · 118 citations · Cited by this paper
  32. Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma · Jason Yongsheng Chan · 2020 · 112 citations · Cited by this paper
  33. Growth Attenuation of Cutaneous Angiosarcoma With Propranolol-Mediated β-Blockade · William D. Chow · 2015 · 94 citations · Cited by this paper
  34. An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial) · Cyrus R. Mehta · 2018 · 78 citations · Cited by this paper
  35. R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma · Jeroen Paardekooper Overman · 2019 · 66 citations · Cited by this paper
  36. Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment · Jalal A. Khan · 2017 · 54 citations · Cited by this paper
  37. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma · Robin L. Jones · 2022 · 52 citations · Cited by this paper
  38. I-SPY 2 — A Glimpse of the Future of Phase 2 Drug Development? · David T. Harrington · 2016 · 48 citations · Cited by this paper
  39. The proteomic landscape of soft tissue sarcomas · Jessica Burns · 2023 · 48 citations · Cited by this paper

Source: OpenAlex (CC0)